iMer, a naturally occurring MERTK splice variant, binds to GAS6 to decrease platelet activation and thrombus...

Area of Science:

• Biochemistry
• Hematology
• Molecular Biology

Background:

• Platelet activation is crucial for hemostasis but can lead to pathological thrombosis when unopposed.
• The Growth Arrest-Specific Gene 6 (GAS6)/Mer receptor tyrosine kinase (MERTK) pathway plays a significant role in platelet activation and thrombus stabilization.

Purpose of the Study:

• To investigate the role of a naturally occurring MERTK splice variant, iMer, in regulating platelet function and thrombus formation.
• To explore the therapeutic potential of iMer in preventing thrombosis.

Main Methods:

• Incubation of human and murine platelets with iMer, a truncated GAS6 decoy receptor.
• Ex vivo platelet function assays including aggregometry, P-selectin expression, and collagen-induced spreading.
• In vivo studies using a collagen/epinephrine-induced pulmonary embolism mouse model to assess survival and bleeding times.

Main Results:

• iMer significantly reduced platelet activation in ex vivo assays, comparable to anti-GAS6 antibody treatment.
• iMer treatment improved survival in a mouse model of pulmonary embolism without increasing bleeding time.
• iMer acts by decreasing MERTK phosphorylation, thereby inhibiting platelet activation.

Conclusions:

• The GAS6/MERTK signaling pathway is critical for platelet activation and thrombus formation.
• iMer, by acting as a GAS6 decoy, effectively inhibits platelet function and thrombus stabilization.
• Targeting the GAS6/MERTK pathway with agents like iMer holds therapeutic promise for treating and preventing thrombosis.